Clinical trial
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients
NCT00233597 · AMAG Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00233597 |
|---|---|
| Title | Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients |
| Official title | A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Hemodialysis Patients Who Are Receiving Supplemental EPO Therapy |
| Lead sponsor | AMAG Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia |
| Intervention type | Drug |
| Interventions | ferumoxytol or oral iron |
| Enrollment | 230 |
| Start date | Aug 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Oct 6, 2005 |
| Last update posted | Apr 4, 2022 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: